
Screen children in schools to find lazy eyes early, experts say
Ellen and Robert Hopkins say they were devastated to find out their son Harry had a lazy eye when they brought him for his first test when he was six-and-a-half years old.Between two and five per cent of children like Harry are diagnosed with amblyopia every year.The UK National Screening Committee recommends vision screening for children aged four to five, but about 11% of local authorities do not offer it in schools.Harry has been wearing a patch for the past few months, but his progress has tapered off since he reached his seventh birthday."We'd definitely like to have known about it earlier," mum Ellen says."If we'd known about it when he was three or four, or perhaps at the start of school, then he would have had longer to work on it."Harry's dad Robert said it was a "fluke" they brought him for an eye test, after he thought he was looking past him when they were having a chat after dinner in their home in Derbyshire."When I was a child I was tested in school, I can't believe kids aren't tested because with conditions like this you have a limited amount of time to make an improvement or not," he added.Craig Murray, chair of BIOS, says it is a hard condition for parents to spot early, and that it is a "postcode lottery" for families on whether they are offered screening or not."We are finding more of those cases of older children who are coming in and they weren't screened, and now it's too late for them to have that amblyopia treated," he said.
Around 75,000 children now live in areas that do not offer school screening, according to a BIOS survey.In areas like Derbyshire, Lincolnshire and North Yorkshire, parents are instead given advice in their child's early development checks, or are signposted towards free NHS tests at their local optician.Others invite parents to complete a digital health screening questionnaire when children start school to highlight any concerns.Jenny Smedley, who carries out vision screening in Sheffield schools, says it is a good way to make sure most children are included.In groups of four, she takes the reception children at Marlcliffe Primary School out to the IT room to be tested.About 800 children have been referred on for further checks so far this year in the county."Parents often say to us, 'There is no way we would have known that there was a problem if screening wasn't there,'" she says."And if they weren't picked up, they wouldn't be able to access certain jobs later on in life, or even drive a car when they're older, so it's significantly important."
Marlcliffe Primary School's head teacher Clare Hayes agrees."It can be difficult for families with busy lives to make appointments at the opticians," she says. "And as parents and teachers, we may not always detect difficulties that children are having with their vision because the children have adapted and got used to that being their sight."Cllr David Fothergill, from the LGA, says he would like to see an increase in the public health grant which funds school-based screening, so that councils can commission and deliver the full range of services needed to improve child health.He says he believes the government's recent spending review overlooked public health funding.But the government said a £200m boost in funding, announced earlier this year, would help support local authorities to tackle the root causes of ill health, and build healthier communities nationwide.Experts say that parents should still bring their children for regular NHS-funded eye tests from the age of three or four every one to two years - even if they do live in areas that screen in schools.
Daniel Hardiman-McCartney, from the College of Optometrists, says school vision screening is a good safety net for children's vision, but it is not the same as an eye test at a local opticians - and both are important.Recent research by the college found many parents are confused about their children's eye health, and only take them for a test if they notice a problem.Harry's parents Ellen and Robert are encouraging everyone to make sure they get their child's eyes tested early, even if they are not able to read yet.The progress in Harry's right eye is being closely monitored to see if patching is still making a difference, and they say it is thankfully not stopping him from doing his favourite thing – reading.Visual journalism by Kady Wardell and Katherine Gaynor
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Guardian
28 minutes ago
- The Guardian
Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?
Eli Lilly, the US manufacturer of the weight loss jab Mounjaro, has said the price will rise by 170% in the UK. From September, the price of the drug will increase with a month's supply of the highest dose rising from £122 to £330. The change comes as Donald Trump ramps up pressure on drugmakers to increase their prices for Europeans so that they can make them more affordable for Americans. We'd like to hear from people who use Mounjaro and how the change in cost might affect them. Have you explored switching to a different medication? Are you worried you will have to stop and might put weight back on? You can tell us how the new price of Mounjaro will affect you by filling in the form below, or messaging us. Please include as much detail as possible. Please include as much detail as possible. Please note, the maximum file size is 5.7 MB. Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian. Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian. If you include other people's names please ask them first. Contact us on WhatsApp at +447766780300. For more information, please see our guidance on contacting us via WhatsApp. For true anonymity please use our SecureDrop service instead. If you're having trouble using the form click here. Read terms of service here and privacy policy here.


Daily Mail
3 hours ago
- Daily Mail
Father-of-two, 39, thought stomach pain was from 'dodgy sausage' at BBQ... but it was colon cancer - doctors gave him 'months to live'
The first sign something was wrong for Matt Eamer came just days after a family barbeque, celebrating his son's second birthday. The then 39-year-old father-of-two from Redhill, Surrey, dismissed the sudden 'spiky' stomach pain as food poisoning. 'I was speaking to work colleagues over the first week or two and thought I'd cooked a dodgy sausage,' he said. But his pain escalated quickly. After a rushed trip to A&E he was sent home with anti-nausea medication Buscopan, yet still felt dreadful. His wife Sarah, 41, a doula, took him to East Surrey Hospital where scans revealed a 'big blockage' in his large intestine. Surgeons removed two-thirds of his bowel in an emergency op. 'A few days later they confirmed it was cancer,' Matt said. The diagnosis was stage four bowel cancer. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. 'I can still remember the person's voice when she phoned and said, "the plan for your diagnosis has changed… we're talking months not years from a survival point of view",' Matt recalled of the events in September 2020. On his 40th birthday he was told standard chemotherapy had failed and surgeons found the cancer had advanced further. 'It was a very dramatic, movie-like point,' he said. 'It was a pivotal change. They said, "we've gone in, it's gone further, we're going to try these new drugs." My wife Sarah collapsed to the floor.' Matt began fortnightly Cetuximab infusions combined with four daily Encorafenib pills, new immunotherapy drugs approved just months earlier. Designed to buy only 'three to six months', they had a remarkable effect. Within six months, scans showed no trace of cancer. Five years on, he is still clear and continues treatment. 'Hitting five years with stage four is a rarity,' he said. 'You're not on your death bed but you're forced to think about how you spend your time.' In December 2024, he underwent a 14-hour surgery to remove cancerous tissue in his ribcage, followed by heated HIPEC chemotherapy. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. Again, scans showed 'things clear.' Matt, who runs his own design agency, continues working and raising his two children. 'The reality is younger people are able to deal with treatments better and live longer, better lives even if it is stage four,' he said. He adds: 'The reality is the 'bucket and spade things', the little moments. I spend more time looking at my kids' faces, taking them to a show or swimming in the sea — they are heightened. 'It means your ability to be present and focus upon what matters is heightened.' To mark five years since his diagnosis, Matt will join Sir Chris Hoy's charity cycle in Glasgow on September 7, raising funds for Bowel Cancer UK. 'It's marking a milestone in a meaningful, positive way,' he said. Bowel cancer, also known as colorectal cancer, is one of the most common cancers in both Britain and the United States. In the UK around 43,000 people are diagnosed every year, while in the US the figure is more than 150,000. It is the third most common cancer worldwide and the second leading cause of cancer deaths. In older age groups incidence is declining thanks to better screening and awareness, yet in younger people rates are rising sharply, a trend baffling doctors. In England cases among those aged 25 to 49 have surged by around 3.6 per cent per year, one of the steepest increases in Europe, while in America rates in under-50s have been rising by about 2.4 per cent annually over the past decade. Outcomes depend heavily on how early the disease is caught. In the UK one-year survival is around 97 per cent if picked up through screening, but just 49 per cent if discovered in an emergency admission, as was the case for Matt. In the US five-year survival is 92 per cent at stage one but only 13 per cent at stage four. Most people with a diagnosis as advanced as Matt's do not reach the five-year mark, making his story unusual. Risk factors include family history, inflammatory bowel disease, obesity, alcohol, smoking, and diets low in fibre and high in red or processed meats. Researchers are also examining the role of ultra-processed foods, though evidence remains inconclusive, and some studies point to gut bacteria toxins such as colibactin, found in food poisoning, as a possible trigger for early-onset cases. Screening programmes remain vital. In the US guidelines now recommend testing from age 45, while in the UK stool tests are currently offered from 56, with pilot schemes lowering the age to 50. Symptoms to watch for include persistent changes in bowel habits, blood in stools, unexplained weight loss, abdominal pain or bloating, and lumps in the abdomen. Doctors stress that catching the disease early saves lives. Patients diagnosed at stage one are several times more likely to survive long term than those at stage four. But as Matt's case shows, advances in treatment—from new targeted drugs to more effective surgery—are beginning to change what is possible, even in the most serious cases. For him, the experience has redefined life. 'The reality isn't bucket-list dolphins—it's the bucket and spade things,' he said.


The Independent
3 hours ago
- The Independent
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'